Evidence map›Paper›PMID 20510213›Full record

ArticleJournal of the American College of Cardiology2010

Predicting late myocardial recovery and outcomes in the early hours of ST-segment elevation myocardial infarction traditional measures compared with microvascular obstruction, salvaged myocardium, and necrosis characteristics by cardiovascular magnetic resonance.

Eric Larose, Josep Rodés-Cabau, Philippe Pibarot, Stéphane Rinfret, Guy Proulx, Can M Nguyen, Jean-Pierre Déry, Onil Gleeton, Louis Roy, Bernard Noël and 6 more

Registry-linked trialAbstract readCommentComparative Study
PubMed Publisher
In one paragraph

Article in Journal of the American College of Cardiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01311700 (Effect of METOprolol in CARDioproteCtioN During an Acute Myocardial InfarCtion. The ME"Effect of METOprolol in CARDioproteCtioN During an Acute Myocardial InfarCtion"), which is not on this map. Cited by 88 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 1 pooled it
15.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01311700 phase4completednot on this map

Effect of METOprolol in CARDioproteCtioN During an Acute Myocardial InfarCtion. The ME"Effect of METOprolol in CARDioproteCtioN During an Acute Myocardial InfarCtion" (METOCARD-CNIC): A Randomized, Controlled Parallel-group, Observer-blinded Clinical Trial of Early Pre-reperfusion Metoprolol Administration in ST-segment Elevation Myocardial infarctionTOCARD-CNIC Trial.

TypeinterventionalSponsorFundación Centro Nacional de Investigaciones Cardiovasculares Carlos IIIRan2010 to 2017Enrolled221ConditionsMyocardial InfarctionArmsInjectable (i.v.) metoprolol tartrate (up to 15 mg).
3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 1 synthesis or guideline pooled it, 226 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Eric LaroseDépartement Multidisciplinaire de Cardiologie, Institut Universitaire de Cardiologie et de Pneumologie de Québec and Faculté de Médicine de l'Université Laval, Québec City, Québec, Canada. eric.larose@criucpq.ulaval.ca <eric.larose@criucpq.ulaval.ca>
Josep Rodés-Cabau
Philippe Pibarot
Stéphane Rinfret
Guy Proulx
Can M Nguyen
Jean-Pierre Déry
Onil Gleeton
Louis Roy
Bernard Noël
Gérald Barbeau
Jacques Rouleau
Jean-Rock Boudreault
Marc Amyot
Robert De Larochellière
Olivier F Bertrand
Institut universitaire de cardiologie et de pneumologie de Québec · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe aim of this study was to determine whether a very early imaging strategy improves the prediction of late systolic dysfunction and poor outcomes in ST-segment elevation myocardial infarction (STEMI) compared with traditional predictors.

backgroundEarlier prediction of poor outcomes after STEMI is desirable, because it will allow tailored therapy at the earliest possible time, when benefits might be greatest.

methodsOne hundred and three patients with acute STEMI were studied by contrast-enhanced cardiovascular magnetic resonance within 12 h of primary angioplasty and at 6 months and followed >2 years. The primary end point was left ventricular (LV) dysfunction, whereas poor outcomes were a key secondary end point.

resultsTraditional risk factors were only modest predictors of late LV dysfunction. Late gadolinium enhancement (LGE) volume maintained a stronger association to LV ejection fraction change than infarct transmurality, microvascular obstruction, or myocardial salvage during STEMI (p = 0.02). Multivariable logistic regression identified LGE volume during STEMI as the best predictor of late LV dysfunction (odds ratio: 1.36, p = 0.03). An LGE >or=23% of LV during STEMI accurately predicted late LV dysfunction (sensitivity 89%, specificity 74%). The LGE volume provided important incremental benefit for predicting late dysfunction (area under the curve = 0.92, p <or= 0.03 vs. traditional risk factors). Twenty-three patients developed poor outcomes (1 death, 2 myocardial infarctions, 5 malignant arrhythmias, 4 severe LV dysfunction <35%, 11 hospital stays for heart failure) over 2.6 +/- 0.9 years; LGE volume remained a strong independent predictor of poor outcomes, whereas LGE >or=23% carried a hazard ratio of 6.1 for adverse events (p < 0.0001).

conclusionsDuring the hyperacute phase of STEMI, LGE volume provides the strongest association and incremental predictive value for late systolic dysfunction and discerns poor late outcomes.

Indexed as

ElectrocardiographyMagnetic Resonance Imaging, CineVentricular RemodelingAngioplasty, Balloon, CoronaryArea Under CurveCohort StudiesContrast MediaCoronary CirculationFemaleFollow-Up StudiesGadoliniumHumansImage EnhancementLinear ModelsMaleMiddle AgedContrast MediaGadolinium

Identifiers

PMID20510213
OpenAlexW1514303257

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.